Hypercalcemia Management — free guideline decision tool

This tool guides hypercalcemia management by calcium level, symptoms, and renal function, framing fluids, antiresorptives (bisphosphonate/denosumab), calcitonin, and special-etiology therapy.

Mild asymptomatic → treat cause/avoid precipitants. Moderate-severe/symptomatic → IV normal saline (urine output ≥ 100 mL/h, loop diuretic only after fluids) + zoledronic acid (or denosumab if renal impairment) + calcitonin for rapid lowering.

Use to scale treatment: mild asymptomatic disease is managed by cause and precipitant avoidance, while moderate-severe or symptomatic hypercalcemia gets IV saline first-line plus antiresorptive and rapid calcitonin.

Never give a loop diuretic before adequate fluid resuscitation — it worsens calcium handling; reserve it for volume overload after rehydration. (original synthesis · not guideline verbatim) Denosumab is preferred when renal impairment or a bisphosphonate contraindication is present, and for refractory/recurrent cases. Calcitriol-mediated hypercalcemia (vitamin D toxicity, granulomatous disease, lymphoma) responds to glucocorticoids.

For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.

Inputs: Calcium level Mild (< 3.0 mmol/L / < 12 mg/dL), Symptoms Symptomatic, Renal impairment or bisphosphonate contraindication No → Result: Disposition Moderate/symptomatic: aggressive calcium-lowering（First-line fluids: IV normal saline to correct dehydration and promote urinary calcium excretion (target urine output ≥ 100 mL/h); after adequate fluids, add loop diuretic (furosemide) for those at risk of volume overload (heart failure/renal impairment) — never give a loop diuretic before fluids, Inhibit bone resorption: IV bisphosphonate: zoledronic acid 4 mg infused over ≥ 15 min (superior to pamidronate; onset 2–4 days); switch to denosumab in renal impairment, Rapid short-term: Calcitonin 100 IU q6–8h SC/IM is rapid but short-acting; for severe (> 3.5 mmol/L / > 14 mg/dL) combine with a bisphosphonate or denosumab） Inputs: Calcium level Severe (> 3.5 mmol/L / > 14 mg/dL), Symptoms Asymptomatic, Renal impairment or bisphosphonate contraindication Yes → Result: Disposition Severe: urgent combined calcium-lowering（First-line fluids: IV normal saline to correct dehydration and promote urinary calcium excretion (target urine output ≥ 100 mL/h); after adequate fluids, add loop diuretic (furosemide) for those at risk of volume overload (heart failure/renal impairment) — never give a loop diuretic before fluids, Inhibit bone resorption: Denosumab (not renally cleared, suitable for renal impairment or bisphosphonate contraindication; also for refractory/recurrent), Rapid short-term: Calcitonin 100 IU q6–8h SC/IM is rapid but short-acting; for severe (> 3.5 mmol/L / > 14 mg/dL) combine with a bisphosphonate or denosumab）